Sales share of Novo Nordisk's drugs in Chinese diabetes market 2021, by segment
In November 2021, the Danish pharmaceutical company Novo Nordisk controlled more than half of the insulin market in China, in terms of sales volume. Founded in 1923, the firm specializes in producing diabetes medications, which accounted for around 80 percent of its annual sales revenue in 2021.